Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

Inclusion Criteria:

1. Females or Males, 20 to 80 years of age (inclusive).

2. Fitzpatrick Skin Type I - III.

3. Clinical diagnosis of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.

4. Willing to refrain from using systemic corticosteroids or retinoids; or topical
corticosteroids or retinoids on the treated area.

5. Must be able to read, understand and sign the Informed Consent Form.

6. Must be willing and able to adhere to the treatment and follow-up schedule and
post-treatment care instructions.

7. Wiling to have very limited sun exposure and use an approved sunscreen of SPF 50 or
higher on the face every day for the duration of the study, including the follow-up
period.

8. Willingness to have digital photographs taken of the face.

9. Agree not to undergo any other procedure for the treatment of
Erythematotelangiectatic Rosacea and Papulopustular Rosacea during the study.

10. Post-menopausal or surgically sterilized, or using a medically acceptable form of
birth control at least 3 months prior to enrollment and during the entire course of
the study.

Exclusion Criteria:

1. History of prior laser or light based procedures for the face within 6 months of
study participation.

2. Fitzpatrick Skin Type IV - VI.

3. Pregnant and/or breastfeeding.

4. Subject is less than 20 years of age or greater than 80 years of age.

5. Having an infection, dermatitis or rash in the treatment area.

6. Suffering from significant concurrent illness, such as diabetes mellitus,
cardiovascular disease, uncontrolled hypertension, or pertinent neurological
disorders.

7. History of keloid formation, hypertrophic scarring or of abnormal wound healing.

8. History of immunosuppression/immune deficiency disorders such as psoriasis, eczema,
vitiligo, or currently using immunosuppressive medications.

9. Malignant tumors in the target area or history of a malignant skin disease.

10. History of fibromyalgia.

11. History of connective tissue disease, such as systemic lupus erythematosus or
scleroderma.

12. Having a known anticoagulative condition or taking prescription anticoagulation
medications.

13. History of seizure disorders due to light.

14. Any current use of medication that is known to increase sensitivity to light, such as
tetracycline.

15. Having a history of diseases stimulated by heat, such as recurrent herpes simplex in
the treatment area, unless treatment is conducted following a prophylactic regimen.

16. Having undergone any surgery in the treatment area within 6 months of treatment (or
more if skin has not healed completely).

17. History of radiation to the head, neck and/or upper chest.

18. History of pigmentary disorders, particularly tendency for hyper- or
hypo-pigmentation.

19. Undergoing systemic chemotherapy for the treatment of cancer.

20. Systemic use of retinoid such as isotretinoin and/or corticosteroid within 6 months.

21. Topical use of retinoid and/or corticosteroid within 4 weeks of study participation.

22. Any use of gold therapy for disorders such as rheumatologic disease or lupus.

23. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
during the study.

24. Current smoker or history of smoking within 12 months of study participation.

25. Participation in a study of another device or drug within 6 months prior to
enrollment or during the study.

26. As per the Investigator's discretion, any physical or mental condition which might
make it unsafe for the subject to participate in this study.